169 related articles for article (PubMed ID: 1195475)
21. Correlation among host immunocompetence and tumor stage, tumor grade and vascular permeation in transitional carcinoma.
Catalona WJ; Chretien PB
J Urol; 1973 Nov; 110(5):526-8. PubMed ID: 4750895
[No Abstract] [Full Text] [Related]
22. The cancer associated antigen test as an index to failure of complete removal of urological cancers.
Wechsler M; Lo Gerfo P; Feminella J; Lattimer JK
Trans Am Assoc Genitourin Surg; 1972; 64():85-7. PubMed ID: 4347503
[No Abstract] [Full Text] [Related]
23. The effects of treatment on delayed cutaneous hypersensitivity responses (DNCB, croton oil, and recall antigen) in patients with genitourinary cancer.
Elhilali MM; Brosman SA; Vescera C; Paul JG; Fahey JL
Cancer; 1978 May; 41(5):1765-70. PubMed ID: 647626
[No Abstract] [Full Text] [Related]
24. Skin reactivity to dinitrochlorobenzene in cancer patients.
Jassem J; Serkies K
Neoplasma; 1980; 27(5):589-93. PubMed ID: 7231615
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic implications of cellular immune defects in operable cancer patients revealed by dinitrochlorobenzene skin contact sensitivity.
Ketcham AS; Chretien PB
Panminerva Med; 1975; 17(5-6):174-8. PubMed ID: 1057759
[No Abstract] [Full Text] [Related]
26. DNCB and PPD skin tests and prognosis in 152 patients with breast cancer. A prospective 2-year follow-up.
Munzarová M; Kovarík J; Hlávková J; Popelínský L; Lauerová L
Neoplasma; 1985; 32(1):45-50. PubMed ID: 3982560
[TBL] [Abstract][Full Text] [Related]
27. The value of urinary neopterin as an immunological parameter in patients with malignant tumors of the genitourinary tract.
Frick J; Aulitzky W; Fuchs D; Hausen A; Joos H; Reibnegger G; Wachter H
Urol Int; 1985; 40(3):155-9. PubMed ID: 3874460
[TBL] [Abstract][Full Text] [Related]
28. Delayed cutaneous hypersensitivity in patients with prostatic adenocarcinoma.
Huus JC; Kursh ED; Poor P; Persky L
J Urol; 1975 Jul; 114(1):86-7. PubMed ID: 1142506
[TBL] [Abstract][Full Text] [Related]
29. [The prognostic significance of the immune status (DNCB-test) in patients with carcinoma of the bladder, checked by observation of the course of disease (author's transl)].
Flamm J; Burkert S
Wien Med Wochenschr; 1981; 131(13-14):339-43. PubMed ID: 7281701
[TBL] [Abstract][Full Text] [Related]
30. [DNCB test and immune competence. Analysis of patients with urologic neoplasms].
Klippel KF; Walz HP; Kreutz G; von Moltke T
MMW Munch Med Wochenschr; 1978 Aug; 120(31):1027-8. PubMed ID: 308155
[No Abstract] [Full Text] [Related]
31. Host immunocompetence in genitourinary cancer: relation to tumor stage and prognosis.
Catalona WJ; Tarpley JL; Potvin C; Chretien PB
Natl Cancer Inst Monogr; 1978 Dec; (49):105-10. PubMed ID: 311891
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the immunocompetance of patients with transitional cell carcinoma of the bladder.
Adolphs HD; Steffens L
Urol Res; 1977; 5(1):29-33. PubMed ID: 855056
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of skin testing with dinitrochlorobenzene in patients with head and neck cancer.
Osoba D; Kersey PA; Clark RM; Rosen IB
Can J Surg; 1980 Jan; 23(1):43-4. PubMed ID: 7363157
[TBL] [Abstract][Full Text] [Related]
34. Sequential evaluation of DNCB reactivity in patients with primary lung cancer. Correlation with prognosis.
Inoue H; Ishihara T; Kobayashi K; Fukai S
J Thorac Cardiovasc Surg; 1978 Oct; 76(4):479-82. PubMed ID: 703354
[TBL] [Abstract][Full Text] [Related]
35. Dinitrochlorobenzene skin sensitization and peripheral lymphocyte count: predictors of survival in head and neck cancer.
Maisel RH; Ogura JH
Ann Otol Rhinol Laryngol; 1976; 85(4 Pt 1):517-22. PubMed ID: 949158
[TBL] [Abstract][Full Text] [Related]
36. Immunocompetence of patients with transitional cell carcinoma as measured by dinitrochlorobenzene skin tests and in vitro lymphocyte function.
Bean MA; Schellhammer PS; Herr HW; Pinsky CM; Whitmore WF
Natl Cancer Inst Monogr; 1978 Dec; (49):111-4. PubMed ID: 155219
[TBL] [Abstract][Full Text] [Related]
37. Carcinoembryonic antigen and urothelial carcinoma.
Hall RR; Laurence DJ; Neville AM; Wallace DM
Br J Urol; 1973 Feb; 45(1):88-92. PubMed ID: 4690154
[No Abstract] [Full Text] [Related]
38. Cellular immunity in bladder cancer patients.
Guinan P; McKiel C; Flanagan M; Bhatti R; Pessis D; Ablin RJ
J Urol; 1978 Jun; 119(6):747-9. PubMed ID: 660759
[TBL] [Abstract][Full Text] [Related]
39. [The DNCB skin test and its comparison with the radioimmunological determination of CEA in some types of neoplasms].
Bianucci P; Pastorino G; De Rossi O
Minerva Med; 1979 May; 70(25):1795-801. PubMed ID: 572515
[TBL] [Abstract][Full Text] [Related]
40. The predictive value of 2,-4, dinitrochlorobenzene skin testing in patients with bilharzial bladder cancer.
El-Mahrouky AS; Dawson DV; Paulson DF; Sanfilippo F
J Urol; 1983 Mar; 129(3):499-501. PubMed ID: 6834532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
